Influence on the Start of Thromboprophylaxis on the Incidence of Thrombotic and Hemorrhagic Complications

O.M. Kozina, Ye.N. Klihunenko

Abstract


200 patients were examined, depending on the type and mode of thromboprophylaxis they were divided into 6 groups: group 1 — unfractionated heparin (UFH), 5,000 IU in standard mode, group 2 — nadroparin calcium, 9,500 anti-Xa IU 2 hours before the operation, group 3 — enoxaparin sodium, 2,500 IU 2 hours before surgery, group 4 — enoxaparin sodium, 2,500 IU 8 hours prior to surgery, group 5 — bemiparin sodium, 2,500 IU 2 hours before the operation, group 6 — bemiparin sodium, 2,500 IU 6 hours after surgery and then 1 time a day for 7 days after it. Bemiparin sodium, regardless of the start time of thromboprophylaxis, as well as pre-operative start of nadro­parin calcium, reduces intraoperative blood loss by 26.1 %. Intraoperative blood loss on the background of enoxaparin sodium and UFH with the start of thromboprophylaxis 2 hours before the operation is the same, whereas in thromboprophylaxis with enoxaparin sodium, started 8 hours before, increased by 4.6 %. Enoxaparin sodium in the preoperative period significantly increases the incidence of wound bleeding and increases the incidence of bleedings in the postoperative period. Thromboprophylaxis using bemiparin sodium, regardless of its start, provides the least number of ecchymosis in the place of drug injection, reduces wound bleeding in the total absence of thromboembolic complications.


Keywords


thromboprophylaxis; planned abdominal surgery; hаemostasis; thrombosis; hypercoagulation

References


Hirsh J. Antithrombotic and Thrombolytic Therapy / J. Hirsh, P. Chair, G. Guyatt; ACCP Guidelines (8th ed.) // Chest. — 2008. — Vol. 133. — P. 71-109.

Anticlotting drugs and regional anaesthetic techniques: comparative update of the safety recommendations / J. Llau, J. Andres, C. Gomar [et al.] // EJA. — 2007. — Vol. 24. — P. 387-398.

Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines / C. Samama, P. Albaladejo, D. Benhamou [et al.] // EJA. — 2006. — Vol. 23. — P. 95-116.

Observational study of bemiparin, first dose admini­stered 6 hours after surgery, in hip or knee replacement surgery / J. Abad, A. Gomez-Qutes, J. Martinez-Gonzales [et al.] // Pathophysiol. Haemost. Thromb. — 2007. — Vol. 36 (suppl. 1).

Treasure T. NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital / T. Treasure, J. Hill // J. R. Soc. Med. — 2010. — Vol. 103 (6). — P. 21021-21022.

Усенко Л.В. Летальность и заболеваемость, связанные с анестезией. Пути повышения ее безопасности / Л. В. Усенко // Біль, знеболювання і інтенсивна терапія. — 2011. — № 2. — С. 41-45.

The Use of Anti-Xa Assay to Monitor Intravenous Unfractionated Heparin Therapy / A.F. Rosenberg, M. Zumberg, L. Taylor, N. Harris // Journal of Pharmacy Practice. — 2010. — Vol. 23 (3). — P. 210-216.

Macintyre P.E. The scientific evidence for acute pain treatment / P.E. Macintyre, S.M. Walker // Curr. Opin. Anaesthesiol. — 2010. — Vol. 23 (5). — P. 623-628.

Chapman T.M. Bemiparin — a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis / T.M. Chapman, K.L. Goa // Drugs. — 2003. — Vol. 63 (21). — P. 2357-2377.

Perka C. Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants // Thrombosis. — 2011. — 9. — 17.

Balibrea J.L., Altimiras J., Larruzea I., Gormes-Outes A., Martenez-Gonzalez J., Rocha E. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: An audit of practice // International Journal of Surgery. — 2007. — 5(2). — 114-9.

Raskob G.E., Hirch J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopaedic surgery // Chest. — 2003. — 124. — 379S-385S.

Prevention of VTE in Nonorthopedic Surgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / Gould M.K., Garcia D.A., Wren S.M., Karanicolas P.J., Arcelus J.I., Heit J.A., Samama C.M., FCCP // Chest. — 2012. — 141(2) (Suppl.). — e227S-e277S.

Bounameaux H., Perneger T. Fondaparinux: a new pentasaccharide for thrombosis prevention // Lancet. — 2002. — 359. — 1710-1711.

Eikelboom J.W., Quinlan D.J., Douketis J.D. Extended duration prophylaxis against venous thrombo­embolism after total hip or knee replacement; a meta-­analysis of the randomized trials // Lancet. — 2001. — 358. — 9-15.

Sobieraj D.M., Lee S., Сoleman C.I. et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery // Ann. Intern. Med. — 2012. — Vol. 156. — P. 720-727.




DOI: https://doi.org/10.22141/2224-0586.5.68.2015.78543

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru